Condition: Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer · Sponsor: Regeneron Pharmaceuticals
The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| University of Alabama_6th Ave | Birmingham, Alabama, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dana Farber / Harvard Cancer Center | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic - Rochester | Rochester, Minnesota, United States | Recruiting |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Withdrawn |
| Columbia University Medical Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| The Ohio State University Wexner Medical Center | Columbus, Ohio, United States | Recruiting |
| Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | Recruiting |
| Sarah Cannon Research Institute | Nashville, Tennessee, United States | Completed |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
| Prince of Wales Hospital | Randwick, New South Wales, Australia | Completed |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03564340